Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy

HIV Medicine

Volumn 12, Issue 1, 2011, Pages 54-60

  Resino, S ^a   Micheloud, D ^a   Lorente, R ^b   Bellon J ^b   Navarro, MaL ^b   Muñoz Fernández, Maá ^b,c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CSIC   (Spain)

Author keywords

Adiponectin; Children; Highly active antiretroviral therapy; HIV; Leptin; Lipids; Lipodystrophy; Total plasminogen activator inhibitor type 1

Indexed keywords

ABACAVIR; ADIPOCYTOKINE; ADIPONECTIN; ANTIRETROVIRUS AGENT; C PEPTIDE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LEPTIN; LIPOPROTEIN; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; RESISTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; LIPOPROTEIN BLOOD LEVEL; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADIPOKINES; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VIRAL LOAD;

EID: 78650098694     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00837.x     Document Type: Article

References (32)

1. Resino S, Resino R, Micheloud D et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis 2006; 42: 862-869.
2. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007; 166: 13-21.
3. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care 2007; 30: 113-119.
4. Beregszaszi M, Dollfus C, Levine M et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40: 161-168.
5. Guillen S, Ramos JT, Resino R, Bellon JM, Munoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J 2007; 26: 334-338.
6. Dzwonek AB, Lawson MS, Cole TJ, Novelli V. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 121-123.
7. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
8. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am Heart J 2006; 151: 1147-1155.
9. Miller TL, Orav EJ, Lipshultz SE et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr 2008; 153: 491-497.
10. Tassiopoulos K, Williams PL, Seage GR III, Crain M, Oleske J, Farley J. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr. 2008; 47: 607-614.
11. Krause JC, Toye MP, Stechenberg BW, Reiter EO, Allen HF. HIV-associated lipodystrophy in children. Pediatr Endocrinol Rev 2005; 3: 45-51.
12. Verkauskiene R, Dollfus C, Levine M et al. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr Res 2006; 60: 225-230.
13. Kim RJ, Carlow DC, Rutstein JH, Rutstein RM. Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy. J Pediatr Endocrinol Metab 2007; 20: 65-74.
14. Papaevangelou V, Papassotiriou I, Vounatsou M, Chrousos G, Theodoridou M. Changes in leptin serum levels in HIV-infected children receiving highly active antiretroviral therapy. Scand J Clin Lab Invest 2007; 67: 291-296.
15. Garcia-Merino I, De Las Cuevas N, Jimenez JL et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009; 6: 27.
16. CDC. Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998; 47: 1-43.
17. Resino S, Bellón J, Gurbindo D et al. Viral load and CD4+T-cells response to HAART in HIV-infected children: an observational study. Clin Infect Dis 2003; 37: 1216-1225.
18. Sharland M, Gibb D, Giaquinto C. Current evidence for the use of paediatric antiretroviral therapy - a PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee. Eur J Pediatr 2000; 159: 649-656.
19. De Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007; 85: 660-667.
20. Hartman K, Verweel G, DeGroot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 427-431.
21. Cianflone K, Zakarian R, Stanculescu C, Germinario R. Protease inhibitor effects on triglyceride synthesis and adipokine secretion in human omental and subcutaneous adipose tissue. Antivir Ther 2006; 11: 681-691.
22. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
23. Rosicka M, Krsek M, Matoulek M et al. Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptors levels. Physiol Res 2003; 52: 61-66.
24. Spagnuolo MI, Bruzzese E, Vallone GF et al. Is resistin a link between highly active antiretroviral therapy and fat redistribution in HIV-infected children? J Endocrinol Invest 2008; 31: 592-596.
25. Tsiodras S, Mantzoros C. Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: physiologic and therapeutic implications. Am J Infect Dis 2006; 2: 141-152.
26. Nishimura R, Sano H, Matsudaira T et al. Changes in body mass index, leptin and adiponectin in Japanese children during a three-year follow-up period: a population-based cohort study. Cardiovasc Diabetol 2009; 8: 30.
27. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34: 2-11.
28. He G, Andersen O, Haugaard SB et al. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest 2005; 35: 583-590.
29. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 441-449.
30. Squillace N, Zona S, Stentarelli C et al. Detectable HIV viral load is associated with metabolic syndrome. J Acquir Immune Defic Syndr 2009; 52: 459-464.
31. Calmy A, Gayet-Ageron A, Montecucco F et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23: 929-939.
32. Resino S, Correa R, Bellon J, Sanchez-Ramon S, Muñoz-Fernandez M. Characterizing immune reconstitution after long-term HAART in Pediatric AIDS. AIDS Res Hum Retrovir 2002; 18: 1395-1406.